Healthtech funding in H1 2013
European Healthtech startup funding raised during H1 2013.
In H1 2013, 56 European Healthtech companies closed 59 funding rounds and raised €303M in equity funding (excluding debt and grants), up 63.4% versus H1 2012. Debt rounds added €914k. Finland led by capital raised, and Lanzadera was the most active investor. Data as of 6 Nov 2026.
Equity funding
€303M
+63.4% vs H1 2012 · excl. debt & grants · +€914k debt
Funding rounds
59
+63.9% vs H1 2012
Companies
56
Top country
Finland
Rank among sectors
#1
15.2% of sector funding
Debt financing
€914k
0.2% of total
Top-10 round share
80.7%
of disclosed capital
Rounds ≥ €100M
1
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2013 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €15M | 10 |
| Feb | €6.8M | 7 |
| Mar | €41M | 10 |
| Apr | €153M | 12 |
| May | €79M | 9 |
| Jun | €124M | 11 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2013 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2013 | |
|---|---|
| Finland | €111M |
| France | €71M |
| Denmark | €60M |
| Switzerland | €46M |
| Ireland | €40M |
| UK | €36M |
| Spain | €28M |
| Israel | €12M |
Stage mix
by € raisedHealthtech — stage mix, H1 2013 — interactive chart.
Data table
| Healthtech — stage mix, H1 2013 | |
|---|---|
| Grant | €115M |
| Series C | €94M |
| Growth/Late | €65M |
| Series B | €50M |
| Series A | €38M |
| Series D+ | €18M |
| Early VC | €18M |
| Other | €12M |
| Seed | €7.2M |
| Debt | €914k |
Top deals
largest disclosed rounds in H1 2013| Company | Stage | Date | Amount |
|---|---|---|---|
| Biotie Therapies | Grant | Jun 2013 | €111M |
| Symphogen | Growth/Late | May 2013 | €41M |
| Auris Medical | Series C | Apr 2013 | €40M |
| Opsona | Series C | Apr 2013 | €33M |
| GenSight Biologics | Series A | Apr 2013 | €32M |
| STAT-Diagnostica | Series B | May 2013 | €22M |
| Genticel | Series D+ | Apr 2013 | €18M |
| Phagenesis | Series B | May 2013 | €15M |
| vitrolife.com | Growth/Late | Mar 2013 | €15M |
| Treato | Series B | Apr 2013 | €11M |
| EyeTechCare | Series C | Mar 2013 | €10M |
| Dysis Medical | Early VC | Apr 2013 | €8.8M |
| Horizon Discovery | Series C | Jun 2013 | €8.1M |
| Sofinnova Partners | Other | Apr 2013 | €8.0M |
| eZono | Early VC | Jan 2013 | €7.6M |
Top investors
most active in H1 2013, by deal count- Lanzadera2 deals
- Parkwalk Advisors2 deals
- SEED Capital2 deals
- Sofinnova Partners2 deals
- Wayra2 deals
- Abingworth LLP1 deals
- Alven Capital1 deals
- Amadeus Capital Partners1 deals
- Amgen Ventures1 deals
- Amundi Private Equity Funds1 deals